Migraine Treatment: What Actually Helps — From Acute Relief and Prevention to Triggers, and What "Chronic" Changes

Short Answer

Migraine treatment works best when you stop thinking of it as one “migraine pill” and start thinking of it as a two-part plan: treat the attacks you already have, and — if they are frequent, long, or disabling — lower the chance that the next ones happen as often. That split matters because acute and preventive treatment do different jobs in the nervous system and in your life. NICE describes migraine care in the same broad direction: medicines can help relieve an attack, and preventive treatment can be considered when the goal is to reduce recurrence and severity. Mayo Clinic uses the same patient-facing frame: treatment is aimed at stopping symptoms and preventing future attacks. (nice.org.uk)

There is no cure, but migraine is very treatable — and needing a better plan is not a personal failure. In one large US study, "Over 75% of participants with migraine in this population sample were candidates for initiation or modification of migraine prescription treatment", so if your current plan is not working, that is common and worth bringing back to a clinician instead of silently pushing through. (pubmed.ncbi.nlm.nih.gov)

For acute treatment — the medicine you use when an attack is starting or underway — "We consider triptans and gepants, where available, first-line treatment options for the acute treatment of migraine", alongside NSAIDs, anti-nausea medicines, and other options depending on your symptoms and medical history. But “first-line” does not mean “right for everyone”: "Triptans may be prescribed in the absence of contraindications, significant risk of cardiovascular disease, or risk for or history of medication-overuse headache", which is why your clinician should match the choice to your heart and vascular risk, other conditions, prior response, and how often you need rescue medicine. NICE also advises clinicians to account for preference, comorbidities, and adverse-event risk when choosing acute migraine treatment, and it recommends rimegepant in specific adult situations when triptans have not worked well enough, are contraindicated, or are not tolerated. (pmc.ncbi.nlm.nih.gov)

For prevention, the goal is not to “knock out” a single attack. It is to make your migraine pattern less frequent, less severe, shorter, or less disruptive over time. "Traditional migraine therapies (triptans, NSAIDs, beta-blockers, topiramate, antidepressants) remain central but require tailoring to vascular, bone, and metabolic health", while "Newer agents-including calcitonin gene-related peptide monoclonal antibodies, gepants, and ditans-offer effective, non-vasoconstrictive alternatives, especially for women with cardiovascular contraindications". In practice, that means prevention is chosen around your attack frequency, disability, pregnancy possibility, cardiovascular profile, mood, sleep, weight/metabolic health, side-effect tolerance, cost, and access — not just around the name of the drug class. (pubmed.ncbi.nlm.nih.gov)

Under the medicine sits the everyday trigger-and-threshold work: sleep, stress, caffeine, hydration, meals, light, and recovery. That does not mean migraine is “caused by lifestyle.” Migraine is a neurologic disease, and triggers are often the last push on an already sensitive system. Still, the pattern is real enough to track: "Various environmental triggers-including sleep or food deprivation, caffeine intake or withdrawal, stress, and light exposure-have been associated with the onset of migraine attacks". Mayo Clinic also recommends regular sleep and meals, hydration, relaxation strategies, and a headache diary to help identify triggers and track treatment progress. (pubmed.ncbi.nlm.nih.gov)

A wearable cannot diagnose migraine, choose your medication, or prove that a treatment worked. What it can do is give context. If you track sleep, stress, HRV, recovery, symptoms, and attack dates, you may notice that your migraine plan is easier to follow — or harder — during short-sleep weeks, high-stress stretches, skipped meals, caffeine shifts, travel, or hormonal windows. That kind of pattern is not a diagnosis. It is a better conversation with your clinician about the weeks and months over which migraine care actually plays out.

Migraine treatment and the felt vs. measured gap — what our data shows

Among 396 Welltory users who self-report migraine compared with 3,749 users who do not, the pattern that matters for treatment is a split between what people feel and what a wearable can easily “see.” A single wearable reading did not cleanly separate the two groups: resting heart rate (65.5 vs 62.5 bpm), morning HRV score (3.11 vs 3.11), sleep score, morning health score, and recovery were close to overlapping — and where small gaps appear, they largely reflect the cluster of co-occurring conditions this group tends to carry, not migraine on its own. The clearer separator was the felt load. Among users who logged a brain-fog check-in, the migraine group flagged brain fog markedly more often — about 49% vs 25% — and that gap still held when we compared people carrying the same number of other self-reported conditions, so it tracks with migraine itself rather than a heavier overall condition load. That brain-fog gap is the reportable finding here.

For treatment, the takeaway is deliberately modest. Migraine burden is real, but it may show up more clearly in how you feel, function, and recover than in one day’s HRV or sleep score. The useful signal is your own baseline and trigger pattern over time. That is why migraine care is built around attack timing, disability, medication response, trigger patterns, medication-overuse risk, and clinician-chosen treatment — not around chasing a single wearable metric.

This is a first-party pattern from a self-identified group of Welltory users, not a clinical diagnosis, and it is not a way to diagnose, treat, or predict migraine. The figures are self-reported, anonymized, and aggregated; no individual user is identifiable. See the “How we made it” note for methodology.

Migraine treatment at a glance — acute, preventive, and everyday layers

Migraine treatment is not one ladder that everyone climbs in the same order. It has two medical jobs: stop or shorten the attack you're in (acute) and, when attacks are frequent or disabling, reduce how many you get (preventive). Those jobs sit on a base of trigger and lifestyle work — sleep, meals, hydration, caffeine consistency, stress load, pacing — because the migraine brain is more likely to tip into an attack when its threshold is already low. Your plan is matched to your attack pattern, aura status, cardiovascular risk, pregnancy plans, other conditions, and how often you need acute medicine. Mayo Clinic describes migraine medicines in those same two broad categories — acute medicines taken during attacks and preventive medicines used to reduce future attacks — and notes that treatment choice depends on headache frequency, severity, nausea/vomiting, disability, and other medical conditions. (mayoclinic.org)

The scale of unmet need is real: "Over 75% of participants with migraine in this population sample were candidates for initiation or modification of migraine prescription treatment". In the OVERCOME (US) study, 77.1% of 59,001 participants with migraine met criteria for prescription-treatment initiation or modification, including acute needs, preventive needs, or both. (pubmed.ncbi.nlm.nih.gov) None of the medication rows below should be chosen from a checklist — class, suitability, and dose are clinician decisions, and several classes carry specific cautions around aura, cardiovascular disease, pregnancy, and medication overuse.

This table is coverage-level and intentionally uses no doses. The class-to-purpose pairings align with major clinical sources: the American Headache Society consensus update describes newer acute and preventive options and emphasizes individual characteristics and preferences; NICE supports triptans/NSAIDs/antiemetics for acute care and preventive options such as topiramate or propranolol; FDA labeling identifies ubrogepant as an acute CGRP receptor antagonist, rimegepant as both acute and preventive for episodic migraine, and onabotulinumtoxinA as prophylaxis for adult chronic migraine. (pubmed.ncbi.nlm.nih.gov)

The big picture: no cure, but very treatable — acute + preventive, matched to you

There is no cure for migraine, and that framing is not defeatist — it keeps the plan honest. NINDS states plainly that migraine currently has no cure, but treatments can help manage symptoms. The goal is not to “fix” the brain once and for all; it is to manage two things: the attacks you have now, and, if they are frequent or disabling, how often they come back. Those are different medical jobs. Acute treatment is for the attack. Preventive treatment is for the pattern. Most good plans use both when the pattern calls for it. (ninds.nih.gov)

That is why “this could probably be working better” is a valid reason to see a clinician. "Over 75% of participants with migraine in this population sample were candidates for initiation or modification of migraine prescription treatment". In plain English: under-treatment is common, and needing a treatment review does not mean you failed at self-care. (pubmed.ncbi.nlm.nih.gov)

“Chronic migraine” is a specific clinical category, not just “a lot of migraines,” and it changes the plan. The ICHD-3 criteria, reproduced in NCBI Bookshelf, define chronic migraine as headache on at least 15 days per month for longer than 3 months, in someone with a history of migraine, with migraine features on at least 8 days per month and not better explained by another headache diagnosis. (ncbi.nlm.nih.gov) A search for “how to cure chronic migraine in one day” or a “natural way to cure chronic migraine” is understandable — pain makes people look for an exit. But it sets the wrong expectation: there is no one-day cure and no universal fix. There is a plan matched to you, and it often gets adjusted over time.

Acute treatment — stopping or shortening the attack

Acute treatment — also called “abortive” treatment — is what you take during an attack to stop or shorten it. Options range from simple analgesics and NSAIDs for some milder attacks to migraine-specific medicines. Mayo Clinic lists pain relievers, triptans, gepants, anti-nausea medicines, and other options under pain-relieving migraine medicines, and notes that acute medicines tend to work best when taken soon after symptoms begin. (mayoclinic.org)

Among migraine-specific acute options, "We consider triptans and gepants, where available, first-line treatment options for the acute treatment of migraine". Triptans have the longest track record: "Triptans have long served as the primary acute migraine treatment, whereas gepants represent a newer, non-vasoconstrictive alternative". But triptans are not for everyone — the choice is individual precisely because "Triptans may be prescribed in the absence of contraindications, significant risk of cardiovascular disease, or risk for or history of medication-overuse headache". Mayo Clinic similarly cautions that triptans might not be safe for people at risk of stroke or heart attack. (mayoclinic.org)

That is where gepants and ditans can matter. Gepants are small-molecule CGRP receptor antagonists: "Gepants, a novel class of calcitonin gene-related peptide (CGRP) receptor antagonists, are increasingly used for acute and preventive migraine treatment". When triptans are contraindicated, not tolerated, or not effective enough, "In those who have contraindications or precautions for triptans, those who do not have an adequate response to triptans, and those unable to tolerate them, gepants are often an appropriate option". A 2026 review of gepants also describes advantages including lack of cardiovascular contraindications and no association with medication-overuse headache, while still noting real-world limits such as cost, access, and drug interactions. (pubmed.ncbi.nlm.nih.gov)

Real-world comparisons so far are nuanced rather than lopsided. In one study, "Gepant users demonstrated 36% higher odds of achieving 24hPR compared to triptan users" — 24-hour pain relief — with no significant difference at the 2-hour pain-freedom mark. That is not a simple “newer is better” story. It is a reminder that the best acute medicine is the one that fits your body, risks, symptoms, access, and response pattern. (pubmed.ncbi.nlm.nih.gov)

Which acute class fits you — and any dose — depends on aura status, cardiovascular risk, pregnancy/breastfeeding, other conditions, drug interactions, and how often you would need to use it. This article gives no drug or dose instructions.

Preventive treatment — having fewer attacks

Preventive treatment has a different job from acute treatment. It is not meant to rescue you from the attack you are already in; it is used when the pattern itself is the problem — attacks that are frequent, long, disabling, poorly controlled, or driving too much acute-medicine use. Mayo Clinic describes preventive medicines as medicines used to reduce how often migraine happens, how painful attacks are, and how long they last. (mayoclinic.org)

The established oral options span several older drug classes: "Traditional migraine therapies (triptans, NSAIDs, beta-blockers, topiramate, antidepressants) remain central but require tailoring to vascular, bone, and metabolic health". In practice, prevention may involve classes such as beta-blockers, topiramate, and tricyclic antidepressants such as amitriptyline, chosen around your medical history rather than by a universal ranking. NICE’s headache guidance supports preventive discussion with options including topiramate or propranolol, while Mayo Clinic lists blood-pressure medicines, antidepressants, antiseizure medicines, Botox, CGRP monoclonal antibodies, and preventive gepants among preventive options. (pmc.ncbi.nlm.nih.gov)

Newer, CGRP-targeted prevention has widened the options. "Newer agents-including calcitonin gene-related peptide monoclonal antibodies, gepants, and ditans-offer effective, non-vasoconstrictive alternatives, especially for women with cardiovascular contraindications". The American Headache Society’s 2024 position statement says CGRP-targeting therapies — monoclonal antibodies and preventive gepants — should be considered a first-line approach for migraine prevention along with previous first-line treatments, without requiring failure of older classes first. (pubmed.ncbi.nlm.nih.gov)

Whichever route you and your clinician choose, the principle holds: "migraine-specific prevention should follow established evidence-based therapies". Prevention is judged over time, not by one good or bad day, and “I’m not sure yet” early in a preventive plan is common. Whether you need prevention at all, which class fits, and any dose are prescribing decisions with monitoring. No doses appear on this page.

Chronic migraine — what changes, and onabotulinumtoxinA

“Chronic migraine” is defined by frequency, and that definition matters because it opens a different treatment toolkit. ICHD-3 criteria list chronic migraine as headache on at least 15 days per month for longer than 3 months, with migraine features on at least 8 days per month, in someone with a migraine history and no better alternative headache diagnosis. (ncbi.nlm.nih.gov)

The clearest chronic-migraine-specific example is onabotulinumtoxinA (Botox). The literature is explicit that "OnabotulinumtoxinA (OnabotA) is an established preventive treatment" for chronic migraine. FDA labeling also indicates onabotulinumtoxinA for prophylaxis of headaches in adult patients with chronic migraine, and NICE recommends botulinum toxin type A as a possible preventive treatment for some adults with chronic migraine when specific criteria are met. (pubmed.ncbi.nlm.nih.gov)

CGRP monoclonal antibodies and preventive gepants are also used in migraine prevention, including in people with chronic migraine depending on the exact product, country, coverage, prior treatments, and clinician judgment. The point of naming chronic migraine separately is not to alarm you. It is that the plan differs. If you are having headaches on many days per month, ask specifically about chronic-migraine-directed prevention rather than only reaching for more acute medicine, which can backfire. Suitability, sequencing, and dose for any of these are specialist decisions. No doses here.

Triggers, sleep, and lifestyle — the everyday base layer

Underneath the medicine is the layer you live in every day. Triggers do not “cause” migraine in the moralizing sense — they are not proof you did something wrong — but they can lower the threshold for an attack. "Various environmental triggers-including sleep or food deprivation, caffeine intake or withdrawal, stress, and light exposure-have been associated with the onset of migraine attacks". NINDS lists too much or too little sleep, stress, skipped meals/low blood sugar, alcohol, hormonal changes, bright or flashing lights, loud noises, and other factors as possible triggers that vary from person to person. (pubmed.ncbi.nlm.nih.gov)

That is why the unglamorous basics — regular sleep, steady meals and hydration, consistent (not erratic) caffeine, stress management, and pacing — are part of treatment, not a lecture bolted onto it. NINDS includes regular meals, enough water, consistent sleep/wake timing, and avoiding personal triggers among practical management steps; MedlinePlus also notes that triggers often combine, and that caffeine or caffeine withdrawal can be relevant. (ninds.nih.gov)

Two honest caveats keep this from becoming a “try harder” message. First, triggers are individual and often work in combinations — a short night plus a skipped meal plus a high-stress day — so blanket elimination diets can create more stress than insight. Second, lifestyle is a foundation, not a guarantee. Many people also need acute and preventive medicine, and needing medicine is not a personal failure. Because sleep and stress are also the axes where Welltory can give you outside context, tracking can support this layer — not replace care, not predict attacks, and not tell you which medicine to take.

Safety: aura, cardiovascular risk, medication-overuse headache, and pregnancy

Some of the most important parts of migraine treatment are the cautions. They are why “just take what worked for a friend” is risky.

Migraine with aura is a safety flag. Beyond drug choice, "migraine without aura often improves after menopause, whereas migraine with aura tends to persist and independently increases the risk of ischemic stroke and other vascular events". A PubMed-indexed consensus review also states that migraine with aura is a risk factor for ischemic stroke and that combined hormonal contraceptives are contraindicated in women with this condition in several major guidance systems. The CDC’s U.S. Medical Eligibility Criteria classifies combined hormonal contraception as category 4 — unacceptable health risk — for migraine with aura. (pmc.ncbi.nlm.nih.gov)

That vascular link is one reason estrogen-containing options are handled carefully: "Oral estrogen, particularly at higher doses, may worsen migraine and elevate vascular risk, especially in women with aura". If you have aura, tell every clinician — primary care, neurology, OB-GYN, urgent care — because it can change what is advisable.

Triptans and cardiovascular risk. As above, triptans are used "in the absence of contraindications, significant risk of cardiovascular disease, or risk for or history of medication-overuse headache". Mayo Clinic similarly says triptans might not be safe for people at risk of stroke or heart attack. Gepants and ditans matter partly because they do not rely on the same vasoconstrictive mechanism, but “non-vasoconstrictive” does not mean “self-serve” — your clinician still has to account for your diagnoses, medications, pregnancy status, and interactions. (mayoclinic.org)

Medication-overuse headache is real. Using acute medicines too many days per month can, paradoxically, drive more headaches. ICHD-3 criteria for medication overuse list regular intake of ergotamine, triptans, opioids, combination analgesics, or mixed acute classes on at least 10 days per month for longer than 3 months, or simple analgesics such as acetaminophen or NSAIDs on at least 15 days per month for longer than 3 months. (ncbi.nlm.nih.gov) Notably, "gepants appear unlikely to produce medication-overuse headache", but if you are reaching for acute medicine on many days each week, that is still a reason to see a clinician about prevention — not to keep escalating on your own.

Pregnancy is a clinician conversation, not a self-serve one. A large CPRD pregnancy-register study found that "Migraine and triptan, amitriptyline and NSAID exposure were all associated with higher risk of miscarriage", while "Beta-blockers were not associated with a higher risk of miscarriage". This was an association study, not proof that each medicine caused miscarriage, but it is a clear reason that migraine medicine in pregnancy — or when trying to conceive — must be individualized with a clinician. (pubmed.ncbi.nlm.nih.gov)

For newer drugs, "Potential signals related to pregnancy outcomes were detected for rimegepant and ubrogepant, warranting cautious interpretation and further investigation". “Signal” does not mean proven harm; it means the safety picture is still being clarified. If you are pregnant, planning pregnancy, or breastfeeding, do not start, stop, or continue migraine medicine without talking to your clinician. None of this is a reason to fear treatment — it is the reason treatment is individualized. No doses appear on this page.

Stress, sleep, and the tracking angle — what Welltory can and can't do

Migraine’s everyday layer — sleep, stress, recovery, caffeine regularity, pacing — is partly measurable from the outside. That is where tracking can help. But the scope has to be clean: Welltory does not track migraine, diagnose migraine, predict attacks, treat migraine, or tell you which medicine to take, and it has no migraine-specific tracking feature. What it can do is help you watch the lifestyle side of your plan: whether your sleep timing is getting more regular, whether high-stress low-recovery stretches are clustering, whether caffeine timing is drifting, and whether your body is staying in a depleted pattern over the weeks and months migraine care plays out over.

In our own migraine cohort, the “objective” numbers people often expect a tracker to move — resting heart rate, HRV score, sleep score, recovery — barely separated people who self-report migraine from those who do not. The bigger difference showed up in how people felt — most clearly self-reported brain fog (see the data note above). That is the honest framing: tracking is context for the conversation, useful for spotting lifestyle patterns and bringing a dated record to your clinician. It is not a diagnosis, not attack prediction, and not proof that a treatment is working.

Putting it together — and knowing when to escalate

Because migraine varies so much, the “right” treatment is really the right combination, revisited over time: a trigger-and-lifestyle base, a reliable acute plan for attacks, and — when attacks are frequent or disabling — prevention, with chronic migraine getting its own specific options. Mild, infrequent attacks may be managed with acute treatment and lifestyle. Frequent or disabling attacks, long attacks, poor response to acute medicine, or reaching for acute medicine on many days are reasons to ask about prevention. Mayo Clinic notes that preventive medicine may be recommended when headaches are long-lasting, severe, frequent, or not responding well to treatment; the American Headache Society consensus emphasizes that treatment integration should be guided by benefit, patient characteristics, and preferences. (mayoclinic.org)

If first-line care is not working — attacks are not improving, medicine is not tolerated, you are stuck in a cycle of daily painkillers, or the diagnosis is uncertain — return to your clinician or ask for referral to a neurologist or headache specialist. That is not “making a fuss.” It is how migraine care is supposed to work: pattern, response, safety, adjustment.

⚠️ Red flag — don't wait: most headaches are not dangerous, but some serious conditions can mimic or accompany migraine. Seek urgent care for a sudden “worst-ever” thunderclap headache, headache with fever and stiff neck, new neurological symptoms such as weakness, numbness, confusion, trouble speaking, or trouble seeing that are not your usual aura, headache after a head injury, headache that steadily worsens over days, or a first or clearly different headache after age 50. Mayo Clinic advises immediate medical attention for thunderclap headache; Cleveland Clinic advises ER care for thunderclap or extremely severe headache and one-sided weakness/paralysis; Harvard Health lists emergency red flags including thunderclap headache, fever with stiff neck, and changed headaches after age 50. (mayoclinic.org)

What Welltory adds: feedback on the lifestyle side, not treatment

Welltory does not diagnose migraine, treat migraine, predict attacks, or tell you which medicine to take. No app should. What it can do is close the feedback loop around the lifestyle tactics you and your clinician choose. Migraine care is judged over weeks and months, not a single day. The useful question is rarely “did I have one good day?” It is “over the next few weeks, are my sleep regularity, stress load, and recovery moving in a better direction as I work this plan?”

Welltory tracks your body’s stress-and-recovery signals — heart rate variability (HRV), resting heart rate, sleep, and recovery — so you are not relying only on memory. After a change to sleep routine, caffeine timing, a stress-management effort, or a new medicine your clinician started, you can bring a dated record of how your body responded. That turns “I think it’s helping” into a pattern your clinician can discuss with you.

Differentiator: Cleveland Clinic and Mayo Clinic explain migraine treatments thoroughly and tell people to work with a clinician, avoid triggers, and keep records. Welltory’s role is different: it gives you a physiological feedback loop for the lifestyle side of the plan — sleep regularity, stress load, and recovery — across the weeks and months migraine care takes. It has no migraine-specific tracking and does not predict attacks; its honest angle is context for the conversation, never treatment, attack prediction, or diagnosis.

How we made it

This page was drafted with AI tools, then edited, fact-checked, and medically reviewed by the Welltory team. See our [Editorial & AI Policy]. We checked medical claims against authoritative migraine references: the American Headache Society consensus update on acute and preventive migraine care, the AAN/AHS evidence-based guideline update on pharmacologic prevention, ICHD-3 diagnostic criteria coverage, and NICE guidance on headache diagnosis and management in people over 12. (pubmed.ncbi.nlm.nih.gov)

The goal was not to tell you what to take. Medication is described only by class and purpose — for example, treatments used during an attack versus treatments used to reduce future attacks — because migraine care depends on your pattern, aura status, other conditions, pregnancy considerations, cardiovascular risk, medication-overuse risk, and clinician judgment. NICE also separates acute relief from prevention and emphasizes discussing benefits and risks with a healthcare professional. (nice.org.uk)

The cohort figures in this page come from a self-identified group of Welltory users, not from clinically diagnosed patients. All figures are reported as anonymized, aggregated data; no individual user is identifiable. They describe patterns in our app data — not a way to diagnose, treat, or predict migraine for any individual person. The reportable finding is the self-reported brain-fog gap (about 49% vs 25%), which held up when comparing people carrying the same number of other conditions; the near-overlapping wearable numbers are included for honesty, not as a migraine test. Before publication, the medical review checked that the article does not diagnose you, prescribe treatment, give medication doses, promise instant or “natural” cures, or soften important cautions around aura, cardiovascular risk, medication overuse, and pregnancy.

Discounts for blog readers: up to 36% off

See what affects your energy, stress, sleep, and daily state with Welltory

Explore your data